Journal: Cancer Immunology, Immunotherapy : CII
Article Title: COVID-19–sensitive tumour response: 2-year assessment of the SARS-CoV-2 humoral response in cancer patients in oncology hospital in Poland
doi: 10.1007/s00262-024-03895-z
Figure Lengend Snippet: Specific humoral response of particular IgG to SARS-CoV-2 infection and COVID-19 vaccination in oncological patients with breast disease over 2 years (monthly). Breast cancer (c) stands out from breast diseases (a , b) in oncological patients. In breast cancer, the statistical significance of the IgG response (d) results from the difference in the post-vaccination response separately for those vaccinated with Pfizer (BNT162b2) (g) and the administration of other vaccines (i) . All of them are working. Surprisingly, the response is more significant in unvaccinated patients (f) than in vaccinated patients (e) for breast cancer. In this group, the humoral response is significant for all three doses (h, i) of the vaccine used (S1, S2, and S3) regardless of the type (and combination of vaccines each other) (j) . It was observed (k) , regardless of vaccination (non-vaccinated group), a more significant increase in the humoral response in treated patients (radiotherapy, chemotherapy, and surgery) and a weaker post-vaccination response in groups of cancer patients over 60 years of age (l) . All of this contribute to the description of the breast cancer anti-infectious response to the COVID-19 pandemic, which may help to understand SARS-CoV-2 fight cancer. S0 (no vaccination), S1 (single vaccine: Johnson&Johnson(J&J), AstraZeneca (AZ), Moderna, Pfizer(COM; Comirnaty), S2A (full two-dose one vaccination) and S2B (two-dose vaccination Pfizer and Moderna), S3, S4, S5-additional vaccination. CHTH-chemotherapy; RTH-radiotherapy; SURG-surgery; n-amount of study samples. P-values represent comparison with groups (*) p < 0.05, (**) p < 0.001, (***) p < 0.0001
Article Snippet: In our study, 82% of the population was vaccinated, including 416 samples from cancer patients who received only the Pfizer-BioNTech BNT162b2 vaccine (Comirnaty).
Techniques: Infection, Vaccines, Comparison
